THLD Profile
Threshold Pharmaceuticals, Inc. (THLD) was a biopharmaceutical company that focused on developing targeted cancer therapies. The company ceased operations in 2017 and is no longer publicly traded.
Before ceasing operations, THLD reported a net loss of $32.4 million for the nine months ended September 30, 2016. The company had cash and cash equivalents of $28.3 million as of September 30, 2016.
Threshold Pharmaceuticals' growth strategy focused on advancing its pipeline of cancer therapies and obtaining regulatory approval for its products. The company's focus on developing innovative cancer treatments enabled it to establish a strong presence in the biopharmaceutical industry.
Investing in biopharmaceutical companies like Threshold Pharmaceuticals carries market risks, including the risk of market volatility, clinical trial setbacks, regulatory hurdles, and competition from other biopharmaceutical providers. Investors should carefully consider these risks before investing in THLD (no longer traded) and consult with a financial advisor to determine if it is an appropriate investment for their portfolio. They should also review the company's public disclosures and financial statements to gain a better understanding of its financial performance and risks.
|
